Plac Test

It is possible now through the PLAC test. The PLAC test brings any intravenous changes that are the reasons for myocardial infarction into view. Through this test, the enzyme activity oscillating from atherosclerotic plaques is measured. The lipoprotein related phospholipase A2 (Lp-PLA2) is made in the atherosclerotic plaques causing inflammation and later on stenosis and is balanced to the blood flow. The PLAC test is a test measuring the activity of this balanced Lp-PLA2 enzyme. The PLAC test was approved by the FDA, U.S. Food & Drag Administration. FDA recommends the PLAC Test as a scanning test in assessment of coronary vein diseases, myocardial infraction, decrease and instantaneous death risk that may arise in the future.       

 

Making a correct risk assessment in preventing development of cardiovascular diseases is one of the most important difficulties that doctors experience. Those who have a slight or medium level of cardiovascular disease risk assessed through traditional risk factors have still under a significant risk for the future 10 years. In about 50% of those with coronary arterial disease history, LDL findings under 100 mg/dL were observed. Blood lipids (cholesterol tests) are mainly inadequate in assessment of the coronary arterial disease. Such problems arising in risk assessment are eliminated by presenting additional prognostic information to clinicians through the PLAC test which is also a FDA approved test, which was not possible with another test previously. 

Morever, the HS-CRP test, which is cardiovascular disease risk symptom, which is also at high level in chronic systemic diseases and infections, is a superior test, as it is only specific for the vessel wall inflammation.   

Taking this test is recommended to everyone with or without cardiovascular disease risk. In some sources, it is assessed as a separate risk factor not depending on traditional risk factors.